VMI
PRVL

VHCP Management II’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

VHCP Management II’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,604
Closed -$32K – 27
2019
Q3 		$32K Buy
+2,604
New +$29.5K 0.01% 21

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VHCP Management II's PRVL Position: Q4 2019 in Review

VHCP Management II sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2019, closing a stake of 2,604 shares — an estimated $32K sold.

VHCP Management II first reported a position in PRVL in Q3 2019 and held it in 1 quarter. The position peaked at $32K in Q3 2019. 46 funds tracked by Wall St. Rank hold PRVL as of Q4 2019.

  • VHCP Management II reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • VHCP Management II sold 2,604 Prevail Therapeutics Inc. Common Stock shares in Q4 2019, an estimated $32K.
  • VHCP Management II first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • VHCP Management II's Prevail Therapeutics Inc. Common Stock position peaked at $32K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2019.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.